These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 16818604)

  • 1. BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP.
    Yu X; Fu S; Lai M; Baer R; Chen J
    Genes Dev; 2006 Jul; 20(13):1721-6. PubMed ID: 16818604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains.
    Yu X; Chen J
    Mol Cell Biol; 2004 Nov; 24(21):9478-86. PubMed ID: 15485915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex.
    Varma AK; Brown RS; Birrane G; Ladias JA
    Biochemistry; 2005 Aug; 44(33):10941-6. PubMed ID: 16101277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 ubiquitylation of CtIP: Just the tIP of the iceberg?
    Barber LJ; Boulton SJ
    DNA Repair (Amst); 2006 Dec; 5(12):1499-504. PubMed ID: 17027345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains.
    Rodriguez M; Yu X; Chen J; Songyang Z
    J Biol Chem; 2003 Dec; 278(52):52914-8. PubMed ID: 14578343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BRCT domain is a phospho-protein binding domain.
    Yu X; Chini CC; He M; Mer G; Chen J
    Science; 2003 Oct; 302(5645):639-42. PubMed ID: 14576433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response.
    Kim H; Huang J; Chen J
    Nat Struct Mol Biol; 2007 Aug; 14(8):710-5. PubMed ID: 17643122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear localization and cell cycle-specific expression of CtIP, a protein that associates with the BRCA1 tumor suppressor.
    Yu X; Baer R
    J Biol Chem; 2000 Jun; 275(24):18541-9. PubMed ID: 10764811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity.
    Sum EY; Peng B; Yu X; Chen J; Byrne J; Lindeman GJ; Visvader JE
    J Biol Chem; 2002 Mar; 277(10):7849-56. PubMed ID: 11751867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HP1 regulates the localization of FANCJ at sites of DNA double-strand breaks.
    Wu W; Togashi Y; Johmura Y; Miyoshi Y; Nobuoka S; Nakanishi M; Ohta T
    Cancer Sci; 2016 Oct; 107(10):1406-1415. PubMed ID: 27399284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of DNA damage on a BRCA1 complex.
    Wu-Baer F; Baer R
    Nature; 2001 Nov; 414(6859):36. PubMed ID: 11689934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCDC98 targets BRCA1 to DNA damage sites.
    Liu Z; Wu J; Yu X
    Nat Struct Mol Biol; 2007 Aug; 14(8):716-20. PubMed ID: 17643121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites.
    Sobhian B; Shao G; Lilli DR; Culhane AC; Moreau LA; Xia B; Livingston DM; Greenberg RA
    Science; 2007 May; 316(5828):1198-202. PubMed ID: 17525341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCT repeats as phosphopeptide-binding modules involved in protein targeting.
    Manke IA; Lowery DM; Nguyen A; Yaffe MB
    Science; 2003 Oct; 302(5645):636-9. PubMed ID: 14576432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response.
    Kim H; Chen J; Yu X
    Science; 2007 May; 316(5828):1202-5. PubMed ID: 17525342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimerization of CtIP, a BRCA1- and CtBP-interacting protein, is mediated by an N-terminal coiled-coil motif.
    Dubin MJ; Stokes PH; Sum EY; Williams RS; Valova VA; Robinson PJ; Lindeman GJ; Glover JN; Visvader JE; Matthews JM
    J Biol Chem; 2004 Jun; 279(26):26932-8. PubMed ID: 15084581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the BRCT binding site of BRCA1 result in hyper-recombination.
    Dever SM; Golding SE; Rosenberg E; Adams BR; Idowu MO; Quillin JM; Valerie N; Xu B; Povirk LF; Valerie K
    Aging (Albany NY); 2011 May; 3(5):515-32. PubMed ID: 21666281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 tumor suppressor and inhibits its enzymatic function.
    Wu-Baer F; Ludwig T; Baer R
    Mol Cell Biol; 2010 Jun; 30(11):2787-98. PubMed ID: 20351172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone ubiquitination associates with BRCA1-dependent DNA damage response.
    Wu J; Huen MS; Lu LY; Ye L; Dou Y; Ljungman M; Chen J; Yu X
    Mol Cell Biol; 2009 Feb; 29(3):849-60. PubMed ID: 19015238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of BRCA1-BRCT/Abraxas Complex Reveals Phosphorylation-Dependent BRCT Dimerization at DNA Damage Sites.
    Wu Q; Paul A; Su D; Mehmood S; Foo TK; Ochi T; Bunting EL; Xia B; Robinson CV; Wang B; Blundell TL
    Mol Cell; 2016 Feb; 61(3):434-448. PubMed ID: 26778126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.